PAVmed Inc. (PAVM) Upgraded to “Sell” at ValuEngine
PAVmed Inc. (NASDAQ:PAVM) was upgraded by stock analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a research report issued on Friday.
PAVmed (NASDAQ:PAVM) opened at 4.4769 on Friday. PAVmed has a 52-week low of $2.54 and a 52-week high of $14.45. The company’s market capitalization is $59.68 million. The stock has a 50 day moving average of $3.69 and a 200-day moving average of $4.67.
PAVmed (NASDAQ:PAVM) last released its earnings results on Monday, August 14th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.14) by $0.01. On average, equities research analysts anticipate that PAVmed will post ($0.72) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This article was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another publication, it was stolen and reposted in violation of US and international copyright law. The original version of this article can be viewed at https://www.watchlistnews.com/pavmed-inc-pavm-upgraded-to-sell-at-valuengine/1537076.html.
In other news, CFO Dennis M. Mcgrath bought 6,000 shares of PAVmed stock in a transaction that occurred on Tuesday, August 22nd. The stock was bought at an average cost of $4.21 per share, with a total value of $25,260.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders purchased a total of 13,885 shares of company stock valued at $56,414 over the last three months. 79.00% of the stock is currently owned by insiders.
An institutional investor recently bought a new position in PAVmed stock. Fusion Family Wealth LLC bought a new stake in PAVmed Inc. (NASDAQ:PAVM) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 55,745 shares of the company’s stock, valued at approximately $251,000. Fusion Family Wealth LLC owned 0.42% of PAVmed at the end of the most recent reporting period. 0.80% of the stock is owned by institutional investors.
PAVmed Company Profile
PAVmed Inc operates as a medical device company in the United States. Its product pipeline includes PortIO, a long-term implantable vascular access device; CarpX, a percutaneous device to treat carpal tunnel syndrome; NextCath, a self-anchoring catheter; DisappEAR: Antibiotic-eluting resorbable ear tube; NextFlo, a disposable infusion pump; and Caldus, a disposable tissue ablation device.
Receive News & Ratings for PAVmed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAVmed Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.